Abstract:Abstract Background Gut microbiota and metabolites have been shown to influence the development of inflammatory bowel disease (IBD). Exosomes derived from human umbilical cord mesenchymal stem cells (HucMSC-Exo) have been identified as a promising biological therapy for the treatment of IBD. Previous studies have described that HucMSC-Exo could modulate gut microbiota. However, the mechanism remains unclear. Here, we explored the role of gut microbiota and metabolites in HucMSC-Exo-mediated amelioration of experimental colitis. Methods Dextran sulfate sodium (DSS) was used to induce colitis. The role of HucMSC-Exo were assessed in colitis mice. Fecal microbiota transplantation (FMT) and sterile fecal filtrate gavage were employed to evaluate the effect of gut microbiota and metabolites. Gut microbiota and metabolites were analyzed through 16S rRNA sequencing and metabolomic profiling. The proportion of CD4+ T cells were phenotyped by multicolour flow cytometry. Results HucMSC-Exo treatment alleviated colon inflammation by regulating flora composition, significantly up-regulated the levels of bacteria such as Bacteroides, Parabacteroides distasonis, and Tannerellaceae. Meanwhile, HucMSC-Exo transformed metabolite short-chain fatty acid (SCFA) profiles, particularly increased butyrate level. Additionally, HucMSC-Exo selectively up-regulated the frequencies of regulatory T (Treg) cells as well as down-regulated the ratio of T helper type 17 (Th17) cells in colonic lamina propria to maintain intestinal immune homeostasis and repaired the colonic mucus barrier. FMT and sterile fecal filtrate gavage were conducted to confirm the above mechanism. Microbiota from HucMSC-Exo-treated mice alleviated the colitis over microbiota from DSS-treated mice. Sterile fecal filtrate from HucMSC-Exo-treated mice and butyrate induced similar beneficial outcomes, such as improved the Th17/Treg balance and repaired the colonic mucus barrier. Collectively, HucMSC-Exo ameliorate colitis by directly modulating gut microbiota and metabolites. Conclusion HucMSC-Exo ameliorated experimental colitis via directly modulating gut microbiota and metabolite butyrate, which could regulate CD4+T cells homeostasis and repair colonic mucus barrier. The findings demonstrated the HucMSC-Exo as a potential gut microbiota and metabolites modulator to treat IBD.

What problem does this paper attempt to address?

This paper aims to explore the mechanism by which exosomes derived from human umbilical cord mesenchymal stem cells (HucMSC - Exo) improve experimental colitis by regulating the gut microbiota and metabolites. Specifically, the research background indicates that the gut microbiota and metabolites have a significant impact on the development of inflammatory bowel disease (IBD), and HucMSC - Exo, as a potential biotherapeutic method, has been proven to be able to regulate the gut microbiota, but its specific mechanism remains unclear. Therefore, the focus of this study is as follows: 1. **Evaluating the role of HucMSC - Exo in experimental colitis**: Using a dextran sulfate sodium (DSS) - induced mouse colitis model to observe the therapeutic effect of HucMSC - Exo. 2. **Investigating the impact of HucMSC - Exo on the gut microbiota**: Analyzing the changes in the gut microbiota of mice after HucMSC - Exo treatment through 16S rRNA sequencing. 3. **Analyzing the impact of HucMSC - Exo on metabolites**: Using metabolomics analysis techniques to detect the level changes of metabolites such as short - chain fatty acids (SCFA) after HucMSC - Exo treatment. 4. **Studying the changes in immune cells**: Detecting the proportion changes of CD4+ T - cell subsets (such as regulatory T - cells [Treg] and helper T - cells 17 [Th17]) in the colonic lamina propria after HucMSC - Exo treatment by multicolor flow cytometry. 5. **Verifying the mechanism**: Further confirming the mechanism by which HucMSC - Exo improves colitis by regulating the gut microbiota and metabolites through fecal microbiota transplantation (FMT) and sterile fecal filtrate gavage experiments. The research results show that HucMSC - Exo repairs the colonic mucosal barrier and alleviates colonic inflammation by regulating the gut microbiota (such as increasing the abundances of Bacteroides, Parabacteroides distasonis, and Tannerellaceae), and metabolites (especially increasing the butyric acid level), as well as regulating the CD4+ T - cell balance (increasing the frequency of Treg cells and reducing the proportion of Th17 cells). These findings provide a theoretical basis for HucMSC - Exo as a potential means of treating IBD.

P175 HucMSC-Exo ameliorate experimental colitis via modulating gut microbiota and metabolites